Holen Sie sich die Stockscreener-App
89.13
1.33%
-1.12
Schlusskurs vom Vortag:
$90.25
Offen:
$89.73
24-Stunden-Volumen:
575.43K
Relative Volume:
0.50
Marktkapitalisierung:
$5.57B
Einnahmen:
$209.18M
Nettoeinkommen (Verlust:
$52.04M
KGV:
125.09
EPS:
0.7125
Netto-Cashflow:
$37.10M
1W Leistung:
+5.19%
1M Leistung:
+11.95%
6M Leistung:
+59.93%
1J Leistung:
+119.87%
1-Tages-Spanne:
$88.42
$92.80
1-Wochen-Bereich:
$84.73
$92.80
52-Wochen-Spanne:
$33.70
$93.25
Protagonist Therapeutics Inc Stock (PTGX) Company Profile
Firmenname
Protagonist Therapeutics Inc
Sektor
Branche
Telefon
(510) 474-0170
Adresse
7707 GATEWAY BLVD., SUITE 140, NEWARK, CA
Vergleichen Sie PTGX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PTGX
Protagonist Therapeutics Inc
|
89.10 | 5.64B | 209.18M | 52.04M | 37.10M | 0.7125 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.54 | 112.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
699.82 | 73.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
417.91 | 56.81B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
891.83 | 55.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
193.92 | 41.92B | 447.02M | -1.18B | -906.14M | -6.1812 |
Protagonist Therapeutics Inc Stock (PTGX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-17 | Eingeleitet | Barclays | Overweight |
| 2025-09-12 | Eingeleitet | Leerink Partners | Outperform |
| 2025-06-17 | Eingeleitet | Citigroup | Buy |
| 2024-12-06 | Eingeleitet | BMO Capital Markets | Outperform |
| 2024-12-06 | Eingeleitet | Goldman | Neutral |
| 2024-11-05 | Eingeleitet | Wedbush | Outperform |
| 2024-09-24 | Eingeleitet | TD Cowen | Buy |
| 2024-09-09 | Eingeleitet | Truist | Buy |
| 2023-10-30 | Eingeleitet | CapitalOne | Overweight |
| 2023-05-25 | Fortgesetzt | Jefferies | Buy |
| 2022-08-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-02-11 | Eingeleitet | BTIG Research | Buy |
| 2021-10-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-11 | Hochstufung | Northland Capital | Market Perform → Outperform |
| 2021-09-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-05-24 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-05-24 | Eingeleitet | Northland Capital | Outperform |
| 2021-01-06 | Eingeleitet | JP Morgan | Overweight |
| 2020-12-16 | Eingeleitet | Piper Sandler | Overweight |
| 2020-09-18 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-15 | Eingeleitet | Jefferies | Buy |
| 2020-05-18 | Bestätigt | H.C. Wainwright | Buy |
| 2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-05-09 | Hochstufung | Stifel | Hold → Buy |
| 2018-12-06 | Eingeleitet | Nomura | Buy |
| 2018-01-29 | Eingeleitet | Stifel | Buy |
| 2017-07-21 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Protagonist Therapeutics Inc Aktie (PTGX) Neueste Nachrichten
Citigroup Maintains Protagonist Therapeutics (PTGX) Buy Recommendation - Nasdaq
PTGX Stock Receives Positive Analyst Rating Update from Citigrou - GuruFocus
Polycythemia Vera Market Positioned for Accelerated Development Through 2034, DelveInsight Finds | Novartis, Protagonist Therapeutics, Italfarmaco, Imago BioSciences, Silence Therapeutics, Ionis Pharm - Barchart.com
Protagonist Announces Icotrokinra Phase 2b ANTHEM-UC Trial Data to be Presented at the United European Gastroenterology Week Berlin 2025 - Livingston Daily
Protagonist Announces Presentations of Clinical Data with Icotrokinra in Plaque Psoriasis and Preclinical Data with PN-881 at the EADV 2025 Congress - Daytona Beach News-Journal
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera - STT Info
Protagonist Announces New Icotrokinra Data in Ulcerative Colitis Showing Potential for a Standout Combination of Therapeutic Benefit and a Favorable Safety Profile in Once-daily Pill - Central New Jersey News
Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Affinity Asset Advisors LLC Reduces Stock Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory - Insider Monkey
What dividend safety score for Protagonist Therapeutics Inc. stock2025 Earnings Surprises & Trade Opportunity Analysis Reports - Newser
How currency fluctuations impact Protagonist Therapeutics Inc. stock2025 Year in Review & Scalable Portfolio Growth Ideas - Newser
How Protagonist Therapeutics Inc. stock compares to growth peers2025 Earnings Surprises & High Accuracy Investment Entry Signals - Newser
Prudential Financial Inc. Has $4.28 Million Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Legal & General Group Plc Grows Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Capital Fund Management S.A. Acquires New Holdings in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics Announces Oral and Poster Presentations on Rusfertide at the 67th Annual ASH Meeting - Foster's Daily Democrat
Protagonist Therapeutics (NASDAQ:PTGX) Nasdaq Futures Therapeutic Edge - Kalkine Media
Skandinaviska Enskilda Banken AB publ Lowers Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Trading Systems Reacting to (PTGX) Volatility - news.stocktradersdaily.com
Ensign Peak Advisors Inc Decreases Stock Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics, Inc. $PTGX Shares Purchased by American Century Companies Inc. - MarketBeat
Protagonist Therapeutics (PTGX) Price Target Increased by 16.48% to 91.65 - MSN
Protagonist Therapeutics, Inc. $PTGX Shares Bought by Creative Planning - MarketBeat
Protagonist Therapeutics to Host Conference Call to Announce an Oral Obesity Development Candidate - Oak Ridger
Why Protagonist Therapeutics Inc. stock remains undervaluedDividend Hike & Fast Moving Stock Trade Plans - BỘ NỘI VỤ
Protagonist Therapeutics, Inc. (PTGX) Stock Forecasts - Yahoo Finance
Protagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance Notice - Newswire.com
Protagonist Therapeutics, Inc. $PTGX Shares Acquired by Universal Beteiligungs und Servicegesellschaft mbH - MarketBeat
Protagonist Therapeutics Reaches Analyst Target Price - Nasdaq
Protagonist Reports Third Quarter 2025 Financial Results and Provides Corporate Update - Daily Commercial
Jefferies Financial Group Inc. Buys 192,126 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
120,159 Shares in Protagonist Therapeutics, Inc. $PTGX Purchased by Segall Bryant & Hamill LLC - MarketBeat
[Form 4] Protagonist Therapeutics, Inc Insider Trading Activity - Stock Titan
Geode Capital Management LLC Buys 20,671 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Intech Investment Management LLC Acquires 2,971 Shares of Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Envestnet Asset Management Inc. Grows Position in Protagonist Therapeutics, Inc. $PTGX - MarketBeat
Protagonist Therapeutics stock maintains Buy rating at Jefferies on pipeline potential - Investing.com Canada
What hedge fund activity signals for Protagonist Therapeutics Inc. stockWall Street Watch & Real-Time Chart Breakout Alerts - newser.com
How rising interest rates impact Protagonist Therapeutics Inc. stockRate Hike & Entry Point Strategy Guides - newser.com
How Protagonist Therapeutics Inc. stock responds to policy changesTrade Risk Summary & Weekly Top Gainers Trade List - newser.com
Officer Molina Surrenders 2,712 Of Protagonist Therapeutics Inc [PTGX] - TradingView
Is Protagonist Therapeutics Inc. stock entering bullish territoryCPI Data & Advanced Technical Analysis Signals - newser.com
What risks investors should watch in Protagonist Therapeutics Inc. stockEarnings Recap Report & Daily Oversold Stock Bounce Ideas - newser.com
Is Protagonist Therapeutics Inc. stock cheap compared to fundamentalsMarket Growth Summary & Weekly Top Gainers Trade List - newser.com
Finanzdaten der Protagonist Therapeutics Inc-Aktie (PTGX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Protagonist Therapeutics Inc-Aktie (PTGX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Waddill William D. | Director |
Oct 10 '25 |
Option Exercise |
6.98 |
12,000 |
83,760 |
17,130 |
| Waddill William D. | Director |
Oct 10 '25 |
Sale |
81.62 |
12,000 |
979,480 |
5,130 |
1.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):